You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
睿昂基因(688217.SH):公司預期能夠維持主營業務的毛利率
格隆匯 09-06 08:50

格隆匯9月6日丨睿昂基因(688217.SH)接受特定對象調研時表示,公司在2022年上半年承擔了上海市部分新冠檢測業務,該業務毛利率較低,約為41.2%。而公司自產試劑的毛利率基本上維持在70%-80%。由於今年年初,我國對新型冠狀病毒感染實施“乙類乙管”,公司承接的新冠核酸檢測業務迅速減少,僅為92.85萬元。公司2023年上半年非新冠業務營業收入為12,663.79萬元,非新冠業務收入佔比上升,使得公司的主營業務毛利率較去年同期提升了11.82%。而且公司的白血病15種融合基因試劑盒、淋巴瘤基因重排試劑盒為國內獨家產品,未來集採概率較低,公司預期能夠維持主營業務的毛利率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account